Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia by Bilal Chughtai, Sirikan Rojanasarot, Kurt Neeser, Dmitry Gultyaev, Stacey L. Amorosi, Neal D. Shore

Get full text

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local th... by Ugo De Giorgi, Martin Gleave, Brad Rosbrook, Stephen J Freedland, Qi Shen, Jennifer Sugg, Gabriel P Haas, Neal D Shore

Get full text

Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patient... by Benjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Lorie Ellis, Neal D Shore

Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysisResearch in context by Stephen J. Freedland, Ugo De Giorgi, Antti Rannikko, Fred Saad, Miguel Ramirez-Backhaus, Anchen F. Nasr, Jasmina I. Ivanova, Arijit Ganguli, Pavol Kral, Arlene L. Reisman, Neal D. Shore

Get full text

On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC by Bernadett E. Szabados, Félix Guerrero-Ramos, Enrique Grande, Petros Grivas, Viktor Grünwald, Marta Carpintero Miguel, Syed A. Hussain, Girish S. Kulkarni, Ana Lisa Wilson, Neal D. Shore, Srikala S. Sridhar, Mary Hoyt, Samantha Strumeier, Jennifer Sutton, Julia Brinkmann, Rosemary E. Teresi, Tilman Todenhöfer

Get full text